Institutional members access full text with Ovid®

Share this article on:

Dramatic Response to Cisplatin Window Therapy in a Boy With Advanced Metastatic Ewing Sarcoma

Trizzino, Antonino MD; Ziino, Ottavio MD; Parafioriti, Antonina MD; Podda, Marta MD; Tropia, Serena MD; Luksch, Roberto MD; D’Angelo, Paolo MD

Journal of Pediatric Hematology/Oncology: August 2013 - Volume 35 - Issue 6 - p 478–481
doi: 10.1097/MPH.0b013e31829d452c
Clinical and Laboratory Observations

Ewing sarcoma (ES) is the second most common type of primary bone malignancy, and retains a high propensity to metastasize; the prognosis of patients with disseminated disease is very poor, with an event-free survival rate of <20%. Current multimodality treatment for ES consists of combined chemotherapy before and concurrent with surgery and local radiotherapy for the involved bone. Cisplatin is one of the most widely used drugs for the treatment of bone tumors in children, but is not currently used in ES. We describe a child with multifocal ES, treated with a phase II trial including a single-drug window therapy, which displayed a dramatic response to 2 courses of cisplatin and had a favorable outcome.

*Department of Pediatric Hematology and Oncology, ARNAS Civico, Di Cristina and Benfratelli Hospital, Palermo

Department of Pathology, Gaetano Pini Hospital

Department of Pediatric Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Supported by the parents’ Association “A.S.L.T.I.- Liberi di crescere” Onlus.

The authors declare no conflict of interest.

Reprints: Paolo D’Angelo, MD, U.O. di Oncoematologia Pediatrica, A.R.N.A.S. Ospedali Civico, Di Cristina e Benfratelli, Piazza Nicola Leotta 4, 90127 Palermo, Italy (e-mail:

Received December 3, 2012

Accepted February 20, 2013

Copyright © 2013 Wolters Kluwer Health, Inc. All rights reserved.